Biotech website design must speak to four audiences who rarely overlap: investors evaluating pipeline and runway, partners assessing collaboration potential, scientific recruits checking publications and lab quality, and patients or advocacy groups looking for hope. The pattern that wins is a serious, evidence-rich editorial site with pipeline transparency, publication depth, and credible leadership profiles.
Why biotech sites are different from any other category
Biotech is one of the few industries where the website is not primarily a sales tool. A biotech company’s product takes years (often decades) to reach market. The website’s job is to attract capital, attract collaborators, attract talent, and maintain credibility with the scientific and regulatory community along the way.
That changes design decisions in fundamental ways. Conversion-rate optimization gives way to reputation management. Marketing copy gives way to clinical and scientific accuracy. Stock imagery gives way to real laboratory photography and named scientific leadership. The visual language is editorial, restrained, and authoritative because the audience expects nothing less.
The pipeline page is the homepage
Investors and partners evaluating a biotech company go to one page first: the pipeline page. This page communicates what programs you are running, what indication each program targets, what stage each program is in (preclinical, Phase 1, Phase 2, Phase 3, regulatory submission), and what milestones are upcoming.
The strongest pipeline pages render this as a visual table or grid. Each row is a program. Each column is a stage. Status bars show progress. Hover or click on any program to expand into the program detail: mechanism of action, indication, primary endpoint, trial registry link (NCT number on ClinicalTrials.gov), partners, and recent updates.
Pipeline transparency norms
Public biotech companies disclose pipeline status in earnings reports, R&D days, and SEC filings. Your website should reflect that disclosure consistently. Inconsistencies between the website pipeline and the latest 10-Q or earnings transcript signal sloppiness to investors and can create regulatory exposure if material information appears on the site before being disclosed publicly.
Private biotech has more flexibility, but the same logic applies. Investors talking to your team will compare what the website says to what the deck says. Consistency builds trust. Disclosure should be coordinated with investor relations and legal.
Scientific publications and conference posters
Biotech credibility flows from the scientific record. A publications section is mandatory. The strongest implementations include peer-reviewed papers, preprints, conference posters, and presentations from major scientific meetings (ASCO, ASH, AHA, AACR, ASGCT, JPM Healthcare Conference).
Each entry should include the title, authors, journal or conference, year, and a link to the abstract or full text. Filterable by program, indication, year, and venue helps investors and recruits navigate efficiently. A downloadable publication list (PDF) is a useful artifact for BD conversations.
Preprints (bioRxiv, medRxiv) are increasingly important. Posting preprints signals scientific engagement and accelerates the conversation with collaborators. Cite them with full bibliographic detail and link to the preprint server.
Investor relations as a first-class citizen
For public biotech, the IR section is one of the most-trafficked parts of the site. It hosts the latest financial filings, earnings presentations, R&D day decks, press releases, regulatory disclosures, and stock information. The IR section also hosts the SEC-required investor disclaimers, forward-looking statements, and safe harbor language.
The strongest IR sections include a clear investor calendar (upcoming earnings, upcoming conferences), an email subscription for press releases and SEC filings, and a download page with the latest investor deck and corporate fact sheet. For private biotech, a simpler “Investors” or “Investor inquiries” page with a contact form for the IR team is the equivalent.
Stock data widgets (price, volume, recent news) can be added but are not required. Many biotech IR pages now skip the live stock widget and link to the relevant exchange page instead, which reduces page weight and avoids data-feed costs.
Leadership and scientific advisory board credibility
Biotech buyers (investors, partners, recruits) want to know who is running the company and who is advising the science. The leadership page is non-negotiable. Each entry includes a real photo, full name, title, prior roles (especially at recognizable pharma, biotech, or academic institutions), and key publications or patents.
The scientific advisory board (SAB) often carries equal weight. Named SAB members from leading academic institutions, government agencies (NIH, FDA), or industry signal that serious scientists believe in the science. Photos and credentials should match the leadership page in quality.
Avoid stock photography. Avoid generic LinkedIn-style headshots. Real editorial portraits in lab or office settings work harder. The visual signal is “these are real people doing real science,” and stock imagery undercuts that message.
Careers and talent acquisition
Biotech competes for scientific talent against pharma, top academic labs, and other biotechs with bigger budgets. The careers page is a key recruiting tool. The strongest implementations go beyond a job board. They include a “what it is like to work here” section, photos of the actual lab and office space, profiles of current scientists and their work, and clear benefits and equity messaging.
For senior science roles, the careers page often links directly to the relevant publications and the relevant program. A computational biology candidate evaluating an oncology biotech wants to see the actual oncology pipeline, the actual computational tools the team uses, and the actual people they would work with. Specificity attracts the right candidates and filters out the wrong ones.
ESG, patient impact, and the corporate story
Biotech increasingly faces pressure from investors, employees, and patient advocacy groups to articulate the corporate story beyond the science. ESG (environmental, social, governance) reporting is becoming standard for public biotech. Patient impact stories are increasingly featured by even early-stage companies, especially in rare disease and oncology.
The pattern that works is a dedicated “Patients” or “Impact” section that tells real patient stories with consent, an annual ESG or impact report (PDF download), and a clear corporate sustainability statement. Avoid making patient stories feel like marketing. Tell them with the gravity and consent the patients deserve.
For broader category-specific design patterns that apply to consulting and corporate sites, the corporate website design guide covers IR, leadership, and ESG architecture in depth.
Visual aesthetic: scientific gravitas
Biotech visual design has converged on what could be called “scientific gravitas”: editorial photography of real labs, real scientists, and real molecular structures, paired with restrained typography and a color palette that signals seriousness. Generic illustration of helices, shields, and abstract networks reads as outdated.
The strongest sites commission real laboratory photography or work with biotech-specialized photographers who can capture authentic lab environments. Where photography is not feasible, real scientific imagery (cryo-EM structures, microscopy, sequencing data) outperforms abstract illustration. The visual signal you want: this company does real science.
Where Framer fits for biotech
Framer suits biotech sites that need to ship a credible, editorial marketing presence without a year-long agency engagement. The component model handles repeated patterns (pipeline rows, publication cards, leadership profiles) cleanly. The CMS handles publications, press releases, and program updates as the science evolves.
For early-stage biotech launching their first marketing site, or established companies rebuilding around a pipeline-first architecture, Framer compresses the build cycle. See framerwebsites.com/industries/healthcare for the healthcare-specific design system.
For the broader patterns shared with healthcare and life sciences sites, the healthcare website design guide covers patient-facing and provider-facing architecture in depth.
Frequently Asked Questions
What is the most important page on a biotech website?
The pipeline page. Investors and partners go there first. It must clearly show every program, the targeted indication, the development stage, the trial registry link, and recent milestones. Get the pipeline page right and the rest of the site has more room to breathe.
Should we publish preprints on the site?
Yes. Preprints (bioRxiv, medRxiv) signal active scientific engagement and accelerate conversations with collaborators. Cite them alongside peer-reviewed papers in your publications section, with full bibliographic information and a link to the preprint server.
How transparent should we be about clinical trial data?
Match what is already public. Link to ClinicalTrials.gov for every active trial. Reference disclosed primary endpoints from your investor materials. Avoid making claims on the website that go beyond what has been publicly disclosed in SEC filings, peer-reviewed publications, or investor presentations.
Do we need a scientific advisory board on the site?
If you have one, yes. Named SAB members from leading academic institutions, NIH, FDA, or industry signal that serious scientists believe in the science. Real photos and credentials, on a page that matches the leadership page in quality, build the credibility investors and partners look for.